- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00030550
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes
RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome.
PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have myelodysplastic syndrome.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
- Determine whether this drug reduces the frequency of leukemia transformation and decreases bone marrow blast percentage in these patients.
- Determine the effect of this drug on neutrophil and platelet production and the number of episodes of febrile neutropenia in these patients.
- Determine the safety of this drug in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to International Prognostic Scoring System score (low and intermediate-1 vs intermediate-2 and high) and transfusion dependence (yes vs no). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive oral thalidomide once daily on weeks 1-24.
- Arm II: Patients receive oral placebo once daily on weeks 1-24. In both arms, patients who have not progressed to leukemia after 24 weeks of therapy may receive open-label thalidomide for an additional 24 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks.
PROJECTED ACCRUAL: A total of 220 patients (110 per treatment arm) will be accrued for this study.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28412
- Ppd Development
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of myelodysplastic syndromes (MDS) of at least 12 weeks duration
- Refractory anemia (RA)
- RA with ringed sideroblasts
- RA with excess blasts
- Chronic myelomonocytic
- No therapy-related MDS
- No myelosclerosis or myelofibrosis occupying more than 30% of marrow space (or assessed as grade 3+ or greater)
- No transformation to acute myeloid leukemia
- No more than 20% blasts in bone marrow
- No more than 5% blasts in peripheral blood
- Patients with an erythropoietin level 100 mU/mL or less must have failed epoetin alfa treatment (i.e., at least 30,000 units of epoetin alfa weekly for at least 6 weeks)
- Transfusion-dependent (received at least 2 units of packed RBCs or whole blood within the past 8 weeks) OR
- Transfusion-independent (no packed RBC or whole blood transfusions within the past 8 weeks with 2 hemoglobin levels (at least 7 days apart) less than 11 g/dL)
No iron deficiency (e.g., absent bone marrow iron store)
- If marrow aspirate is not evaluable, transferrin saturation must be at least 20% and ferritin at least 50 ng/mL
- No uncorrected B12 or folate deficiency
- No other contributing causes of anemia (e.g., autoimmune or hereditary hemolytic disorders or gastrointestinal blood loss)
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2 OR
- Zubrod 0-2
Life expectancy:
- At least 6 months
Hematopoietic:
- See Disease Characteristics
- Absolute neutrophil count at least 500/mm^3
Hepatic:
- Bilirubin no greater than 2.0 mg/dL
- AST and ALT less than 2 times upper limit of normal (ULN)
- Hepatitis B surface antigen negative
- Hepatitis C negative
Renal:
- Creatinine no greater than 1.5 times ULN
Cardiovascular:
- No uncontrolled hypertension
- No clinically significant, symptomatic, unstable cardiovascular disease unrelated to MDS
Pulmonary:
- No clinically significant, symptomatic, unstable pulmonary disease unrelated to MDS
Neurologic:
- No clinically significant, symptomatic, unstable neurologic disease unrelated to MDS
- No history of epilepsy
- No sustained neurologic deficit (e.g., stroke)
- No grade 2 or greater peripheral neuropathy
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use at least 1 highly effective and 1 additional effective method of contraception for 4 weeks prior to, during, and for 4 weeks after study participation
- HIV negative
- No clinically significant, symptomatic, unstable endocrine, gastrointestinal, or genitourinary disease unrelated to MDS
- No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No life-threatening or active infection requiring parenteral antibiotics
- No other serious concurrent illness
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
- More than 7 days since prior hematopoietic growth factors (e.g., epoetin alfa, filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-3)
- No prior thalidomide
- No prior agents intended to inhibit vascular endothelial growth factor or tumor necrosis factor alfa (e.g., etanercept or infliximab)
- No concurrent epoetin alfa
Chemotherapy:
- No concurrent chemotherapy that may be active against MDS
Endocrine therapy:
- More than 30 days since prior androgens
- No requirement for ongoing therapy with systemic corticosteroids
Radiotherapy:
- Not specified
Surgery:
- Not specified
Other:
- More than 30 days since prior treatment for MDS except RBC transfusion or epoetin alfa
- More than 30 days since prior participation in another experimental clinical trial
- More than 30 days since prior experimental drugs
- No other concurrent investigational agents or treatments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: James L. Slack, MD, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- refractory anemia
- refractory anemia with ringed sideroblasts
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
- de novo myelodysplastic syndromes
- previously treated myelodysplastic syndromes
- myelodysplastic/myeloproliferative neoplasm, unclassifiable
- atypical chronic myeloid leukemia, BCR-ABL1 negative
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Leukemia
- Preleukemia
- Anemia
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Thalidomide
Other Study ID Numbers
- DS 01-16
- RPCI-DS-0116
- CELGENE-T-MDS-001
- NCI-G01-2044
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on thalidomide
-
Henan Cancer HospitalFirst Affiliated Hospital Xi'an Jiaotong UniversityRecruitingEsophageal Carcinoma | Lung Cancer, Nonsmall CellChina
-
Norwegian University of Science and TechnologyThe Research Council of Norway; Nordic Myeloma Study Group, GermanyCompleted
-
Changzhou No.2 People's HospitalUnknownEsophageal CancerChina
-
Shanghai Pharmaceuticals Holding Co., LtdCompletedAnkylosing SpondylitisChina
-
Shanghai Jiao Tong University School of MedicineChanghai Hospital; Peking Union Medical College Hospital; Shanghai Zhongshan... and other collaboratorsCompletedGastrointestinal Vascular MalformationChina
-
Valme University HospitalUniversity of SevilleUnknown
-
G.V. (Sonny) Montgomery VA Medical CenterUnknownHepatitis C Virus Infection | Infection | Herpesvirus 2, HumanUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Roswell Park Cancer InstituteCompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Graft Versus Host DiseaseUnited States
-
Washington University School of MedicineCelgene CorporationCompleted